Skip to main navigation

Top bar

Biogen.com Information Request Sign up for Alerts Search

Investor Relations

Overview

News

Events Presentations

SEC Filings Annual Reports

Stock Quote & Chart Analyst Coverage Investor FAQs

Governance Documents Committee Composition & Charters Leadership Code of Business Conduct Contact the Board

News

News

News Category

Year

September 18, 2019

Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients

September 17, 2019

Biogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World Index

September 13, 2019

Eisai And Biogen To Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease

September 12, 2019

New Research Demonstrate Biogen’s Continued Commitment to Improve Care of Patients with Multiple Sclerosis Across Treatment Spectrum

September 11, 2019

Biogen to Report Third Quarter 2019 Financials October 22,2019

September 11, 2019

New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA® (dimethyl fumarate) Over 10 Years

August 27, 2019

Biogen to Present at the Morgan Stanley 17th Annual Global Healthcare Conference

July 30, 2019

Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis

July 23, 2019

Biogen Q2 2019 Revenues Increased 8% to $3.6 Billion

July 1, 2019

Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients

Pagination

First page
Previous page
…
Page 6
Page 7
Page 8
Page 9
Current page 10
Page 11
Page 12
Page 13
Page 14
…
Next page
Last page

Displaying 91 - 100 of 778

Footer

Investors
Careers
Our Stories
Contact Us

Follow us

Bottom

Privacy Policy
Terms & Conditions
Forward-Looking Statements
Community Guidelines

Investor Relations

Overview

News

Events & Presentations

Events
Presentations

Financials

SEC Filings
Annual Reports

Stock Information

Stock Quote & Chart
Analyst Coverage
Investor FAQs

Corporate Governance

Governance Documents
Committee Composition & Charters
Leadership
Code of Business Conduct
Contact the Board

Top bar

Biogen.com

Information Request

Sign up for Alerts

Search

Follow us